Many Breast Cancer Mutations Parallel Mutations in Known Viral Cancers

Introduction:A high incidence of endometrial K-ras mutations has been reported in tamoxifen (TAM)-treated patients with breast cancer. We examined the changes in the frequency of the endometrial K-ras mutations after the cessation of TAM treatment.Methods:DNA was extracted from fresh cytological or polypectomy samples of the endometrium in 28 patients who had undergone TAM treatment of breast cancer. Mutations were detected by an enriched polymerase chain reaction-enzyme-linked minisequence assay (Sumitomo Metal Industry, Inc, Tokyo, Japan). K-ras codon 12 mutations were monitored in these 28 patients.Results:An initial examination detected endometrial K-ras mutations in 13 of the 28 patients. However, repeated examinations performed after cessation of TAM treatment did not detect endometrial K-ras mutations in any of these 13 patients. No endometrial K-ras mutation has been detected in the repeated examinations performed for these patients for more than 2 years since the cessation of TAM treatment. In addition, the 15 patients who did not have endometrial K-ras mutations in the initial examination did not demonstrate them in repeat examinations.Conclusions:The cessation of TAM treatment may reduce the risk of developing endometrial cancers through K-ras mutations.

Download Full-text

Abstract 4467: The role of HOXA5 in the malignant progression of engineered isogenic MCF10A sublines harboring common breast cancer mutations

10.1158/1538-7445.am2018-4467 ◽

2018 ◽

Author(s):

Priya Pai ◽

Guannan Wang ◽

Saraswati Sukumar

Keyword(s):

Breast Cancer ◽

Malignant Progression ◽

Cancer Mutations

Download Full-text

Matching Novel Breast Cancer Mutations With Potential Therapies

Oncology Times ◽

10.1097/01.cot.0000527369.44911.10 ◽

2017 ◽

Vol 39 (22) ◽

pp. 36-37

Author(s):

Ariella B. Hanker

Keyword(s):

Breast Cancer ◽

Cancer Mutations

Download Full-text

Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.

Journal of Clinical Oncology ◽

10.1200/jco.1998.16.7.2417 ◽

1998 ◽

Vol 16 (7) ◽

pp. 2417-2425 ◽

Cited By ~ 323

Author(s):

T S Frank ◽

S A Manley ◽

O I Olopade ◽

S Cummings ◽

J E Garber ◽

...

Keyword(s):

Breast Cancer ◽

Ovarian Cancer ◽

Family History ◽

Sequence Analysis ◽

Detection Methods ◽

Ovarian Cancer Risk ◽

Brca1 And Brca2 ◽

Degree Relative ◽

Increased Risk ◽

Cancer Mutations

PURPOSE Previous studies of mutations in BRCA1 or BRCA2 have used detection methods that may underestimate the actual frequency of mutations and have analyzed women using heterogeneous criteria for risk of hereditary cancer. PATIENTS AND METHODS A total of 238 women with breast cancer before age 50 or ovarian cancer at any age and at least one first- or second-degree relative with either diagnosis underwent sequence analysis of BRCA1 followed by analysis of BRCA2 (except for 27 women who declined analysis of BRCA2 after a deleterious mutation was discovered in BRCA1). Results were correlated with personal and family history of malignancy. RESULTS Deleterious mutations were identified in 94 (39%) women, including 59 of 117 (50%) from families with ovarian cancer and 35 of 121 (29%) from families without ovarian cancer. Mutations were identified in 14 of 70 (20%) women with just one other relative who developed breast cancer before age 50. In women with breast cancer, mutations in BRCA1 and BRCA2 were associated with a 10-fold increased risk of subsequent ovarian carcinoma (P = .005). CONCLUSION Because mutations in BRCA1 and BRCA2 in women with breast cancer are associated with an increased risk of ovarian cancer, analysis of these genes should be considered for women diagnosed with breast cancer who have a high probability of carrying a mutation according to the statistical model developed with these data.

Download Full-text

Lynch Syndrome and Breast Cancer: Case Reports and Literature Review

Surgical Case Reports ◽

10.31487/j.scr.2020.09.15 ◽

2020 ◽

pp. 1-3

Author(s):

Spyridon Marinopoulos ◽

Eleni Papamattheou ◽

Sofia-Dionysia Touriki ◽

Aris Giannos ◽

...

Keyword(s):

Breast Cancer ◽

Lynch Syndrome ◽

Hereditary Cancer ◽

Cancer Genomics ◽

Case Reports ◽

Breast Cancer Case ◽

Cancer Case ◽

Inherited Disease ◽

Cancer Mutations ◽

History Of

In the era of advanced cancer genomics, our knowledge of hereditary cancer mutations continues to expand. Lynch syndrome is one of the hereditary cancer predisposition syndromes associated with an increased lifelong risk of several types of cancer development, such as colorectal, endometrial, ovarian and other. This unique syndrome is an autosomal dominant inherited disease caused by mutations on EPCAM gene or on mismatch repair genes, which lead to microsatellite instability. In this article we will present three such cases visiting our clinic. They had breast cancer and a familial or personal history of malignancy. This article summarizes what we consider important about Lynch syndrome and breast cancer.

Download Full-text